En Es
Categories

Industry News

Global Automated Breast Ultrasound Systems Market to Surpass USD 1.8 Billion by 2025

By Medimaging International staff writers
07 Nov 2019

Image: The global automated breast ultrasound systems (ABUS) market is being driven by increasing government expenditure and rising awareness about breast cancer (Photo courtesy of Philips Healthcare).The global automated breast ultrasound systems (ABUS) market was valued at over USD 0.68 billion in 2018 and is projected to grow at a CAGR 16.1% during the forecast period, 2019-2025 to surpass USD 1.8 billion by 2025, driven by increasing government expenditure and rising awareness about breast cancer. Initiatives such as free check-up camps and symposiums for raising awareness regarding early detection and diagnosis of breast cancer will lead to greater adoption of ABUS in the coming years. However, stringent regulations and guidelines for the approval of ABUS, coupled with the high cost of diagnostic procedure, could hamper the market growth during the forecast period.

These are the latest findings of Global Market Insights, Inc. (Selbyville, DE, USA; www.gminsights.com), a global market research and management consulting company.

ABUS is superior than conventional technologies in the detection of consistent breast lesion growth. ABUS assists during critical processes for identification and characterization of breast lesions, leading to reduced treatment costs. Moreover, ABUS provide precise anatomical images for breast cancer diagnosis, thereby majorly impacting operational and diagnostic efficiency. Increasing advancements in ABUS for accurate diagnosis and timely treatment will increase the adoption of breast ultrasound systems over the coming years.

High breast tissue density, lower childbearing and hormonal imbalance issues among women due to changing lifestyle are the major risk factors for breast cancer, thus providing lucrative opportunities for the growth of the global ABUS market. According to the World Health Organization, approximately 2.1 million patients suffer from breast cancer each year. The rising prevalence of breast cancer globally will generate significant demand for ABUS over the forecast period.

In 2018, the diagnostic imaging centers segment reported revenues of USD 0.65 billion. The adoption of ABUS in diagnostic imaging centers is estimated to witness rapid growth due to the expansion of early diagnosis and detection of cancerous cells in the body. The growing availability of specialized technology-based breast imaging techniques and cutting-edge imaging technologies in diagnostic facilities will augment the growth of the diagnostic imaging centers segment. Furthermore, the increasing number of facilities and healthcare infrastructure in the emerging countries will drive the segmental growth during the forecast period.

Geographically, the US held a share of more than 89.0% in the global ABUS market in 2018. The growing adoption of ABUS for the early detection of breast cancer, coupled with the implementation of government initiatives such as Pink Initiative, funding as well as increased awareness will act as the key drivers of the market growth in the US. Furthermore, the presence of established market players in the US will contribute significantly to the growth of the country’s ABUS market during the forecast period.

The ABUS market in Saudi Arabia is projected to grow at a lucrative CAGR of 20.1% during the forecast period, driven by rapidly emerging cancer diagnosis and treatment in the country. Increasing hospitals and government expenditure offering cost advantages are driving the adoption rate of ABUS in Saudi Arabia. Moreover, an increasing patient pool along with growing research activities for innovating ABUS will further aid the growth of the ABUS market in Saudi Arabia.

Related Links:
Global Market Insights, Inc.



E-mail Print
FaceBook Twitter Google+ Linked in

Additional news

22 Jan 2020
Global Point of Care Testing (POCT) Market to Reach USD 46.7 Billion by 2024
 The global point of care testing (POCT) market is expected to surpass USD 37 billion by 2025, driven mainly by the migration of POCT from the hospital environment to a range of medical environments, including the workplace, home, disaster care and most recently, convenience clinics. POCT now appears to be headed for a bigger role in diagnosis and monitoring patient care. Additionally, growing awareness about early disease diagnosis and prevention has stimulated the demand for POCT for detecting cancer and infectious disease in the early stages. Moreover, the rising incidence of infectious diseases and chronic conditions, such as cardiovascular diseases and diabetes in the developing countries such as India and China, is stimulating the demand for POCT services.
Read More
16 Jan 2020
Radiomic Algorithm Predicts if Patient’s Cancer Can Return 10 Years After Treatment
 A new study by researchers at Penn Medicine (Philadelphia, PA, USA) has found that Magnetic Resonance Imaging (MRI) and an emerging field of medicine called radiomics — which uses algorithms to extract a large amount of features from medical images — could help to characterize the heterogeneity of cancer cells within a tumor and allow for a better understanding of the causes and progression of a person’s individual disease.
Read More
13 Jan 2020
PENTAX Medical Clears CE Mark for New AI-Assisted Polyp Detector
 PENTAX Medical (Tokyo, Japan) has cleared CE mark for DISCOVERY, its Artificial Intelligence (AI) assisted polyp detector designed to support endoscopists in finding potential polyps during a colorectal examination.
Read More
07 Jan 2020
New AI Model Identifies Women Facing Future Risk of Breast Cancer
 Researchers from the Karolinska Institute (Stockholm, Sweden) have developed a sophisticated type of artificial intelligence (AI) which can outperform existing models at predicting which women are at future risk of breast cancer.
Read More
07 Jan 2020
Global EEG Devices Market to Reach USD 2.20 Billion in 2027
 The global EEG (Electroencephalography) devices market was valued at USD 1.12 billion in 2018 and is projected to grow at a CAGR of 7.8 % over the forecast period 2019-2027 to reach USD 2.20 billion in 2027, driven mainly by the increasing prevalence of sleep disorders.

Read More
06 Jan 2020
Google AI System Beats Doctors in Detecting Breast Cancer
 A team of researchers from Google Health (Palo Alto, CA, USA) have developed an artificial intelligence (AI) model which can spot breast cancer in de-identified screening mammograms (where identifiable information has been removed) with greater accuracy, fewer false positives, and fewer false negatives than experts. This can find future applications wherein the model could support radiologists performing breast cancer screenings.
Read More
03 Jan 2020
Nova Biomedical Launches New BioProfile FLEX2 On-Line Autosampler
 Nova Biomedical (Waltham, MA, USA) has launched the BioProfile FLEX2 On-Line Autosampler (OLS), a modular system that connects as many as 10 bioreactors to one FLEX2 analyzer for up to three weeks of walkaway, automated sampling, analysis, and feedback control of key cell culture analytes. The FLEX2 measures up to 16 tests, including pH, gases, metabolites, osmolality, cell density, and cell viability.
Read More
03 Jan 2020
Global Hematology Diagnostic Devices and Equipment Market to Reach USD 2.35 Billion by 2022
 The global hematology diagnostic devices and equipment market was valued at about USD 1.9 billion in 2018 and is projected to grow to at a CAGR of 5.5% to USD 2.35 billion in 2022. The market growth is driven mainly by an increase in the use of hematology diagnostic devices due to the rising prevalence of blood disorders which affect millions of people each year across the world, irrespective of age, race, and sex.
Read More
03 Jan 2020
Global Immunochemistry Diagnostic Devices and Equipment Market to Reach USD 19.24 Billion by 2022
 The global immunochemistry diagnostic devices and equipment market was valued at about USD 16.7 billion in 2018 and is projected to grow at a CAGR of 3.6% to USD 19.24 billion in 2022. The market growth will be driven by an increase in the incidence of target diseases, such as viral infections, cardiovascular diseases, cancer or hormonal disorders worldwide, mainly due to poor lifestyle choices.
Read More
Copyright © 2000-2020 TradeMed.com. All rights reserved. | Terms And Conditions